What 'progressive' actually means for your hip

For most people with hip osteoarthritis, the answer to 'how fast will this get worse?' is: slowly, and unpredictably — but not quickly, and not inevitably towards surgery in the near term.

Structurally, the hallmark change is articular cartilage thinning. Under stable conditions, joint space width typically narrows by a fraction of a millimetre per year — a rate invisible to daily experience but measurable on sequential X-rays over several years. During symptomatic flares, that rate can accelerate, then settle again. The joint's ball-and-socket design means it carries load with every step; unlike some softer tissues, articular cartilage cannot regenerate once lost, so the underlying trend is one way.

Yet the gap between 'visible on X-ray' and 'needing a hip replacement' is substantial. Around 27% of adults aged 45 and over show radiographic signs of hip OA. Over a 10–20-year follow-up, roughly 11–17% of those with established radiographic changes ultimately convert to total hip replacement — meaning more than 80% do not reach surgery within that window. Visible joint changes are not a countdown. A 10-year cohort study (van Berkel, 2021; n=249) found that 53% of participants with clinical hip OA had developed radiographic OA in at least one hip by year ten — but radiographic change and the need for surgery are very different thresholds.

What drives one patient to progress faster than another is where the story becomes more specific.

The stages hip OA typically moves through

Hip OA does not announce itself clearly at first. Early on, the discomfort is typically intermittent groin ache or lateral hip pain during or after activity — a long walk, a stretch of sitting followed by standing. It eases with rest and is easy to dismiss as a muscular twinge or put down to age. Morning stiffness is brief. Most people at this stage move normally between episodes.

As the condition advances, the pattern shifts. Pain becomes more continuous rather than activity-triggered. Morning stiffness extends beyond half an hour. Walking tolerance shortens noticeably. The muscles that stabilise the hip — particularly the abductors and gluteals — begin losing conditioning simply because the joint is being used less.

Later still, pain intrudes at rest and during the night. Range of hip motion narrows in ways that become hard to ignore: putting on socks, getting in and out of a car, or climbing stairs turns into a deliberate effort. An altered, protective gait compounds the muscle weakness already building.

At end stage, imaging shows the joint space has closed entirely, with bone contacting bone. Conservative measures offer little at this point, and hip replacement typically becomes the primary pathway.

Molecular studies of joint tissue suggest a transition window of roughly 16 years — with early-stage OA changes appearing at a mean age of around 43 and late-stage disease around 60 — though the pace differs considerably between individuals.

One honest caveat: symptoms and imaging do not always move in step. Some people have modest radiographic changes yet significant pain; others show advanced imaging findings and manage relatively well functionally. A clinician needs both pieces of information together to make sense of where any individual actually sits on this spectrum.

Who progresses faster — and why

Several factors reliably tip the balance towards faster structural decline, and recognising them helps explain why two people with identical diagnoses can follow very different paths.

Age is the most consistent driver. Hip cartilage cells gradually lose their capacity for self-repair as the joint ages — a process tied to telomere shortening at the cellular level — leaving older tissue with far less biological reserve to draw on.

Body weight adds a mechanical dimension. Greater load across the joint with every step accelerates cartilage stress and loss; higher BMI is an established predictor of faster structural deterioration.

Cardiovascular health is less obvious but clinically significant. In the KHOALA cohort, non-obese patients with cardiovascular disease had 3.45 times greater odds of radiographic hip OA worsening over five years — likely reflecting impaired cartilage nutrition when joint circulation is compromised.

Hip shape is the factor most patients have not considered. Femoroacetabular impingement (FAI) — where the ball or socket has an irregular contour — contributes to an estimated 50% of hip OA cases. A 12-year follow-up study found that untreated FAI hips deteriorated radiographically in 48% of cases; hips that received early treatment worsened in only 28%. A prominent cam bump on the femoral head or a borderline-shallow socket are the morphological features that most reliably predict faster decline.

Finally, persistent pain is itself a structural signal worth taking seriously. A follow-up study found that continuing hip joint pain maps directly to ongoing bone changes on MRI; when pain resolved, those changes resolved too — but when it persisted, so did progressive radiographic worsening. Older age was significantly associated with the group in which both pain and tissue damage continued unchecked.

These are population-level associations, not individual predictions. Which factors apply in a specific case, and how urgently, is a question for clinical assessment.

What early treatment changes about the trajectory

The 12-year follow-up data introduced in the previous section does more than rank risk factors — it reframes the entire logic of early hip care. A 42% relative risk reduction in radiographic OA progression with arthroscopy means that timely treatment was doing something structurally meaningful, not simply masking pain. For FAI-related cases (discussed above), early intervention belongs in the category of disease modification rather than symptom management.

This distinction changes how patients should think about timing. Conservative measures — physiotherapy targeting hip-abductor conditioning, weight management, and activity modification — are not passive; they genuinely reduce the mechanical forces that accelerate cartilage breakdown. But they act on the environment around the joint rather than on the tissue itself. Published evidence suggests they can slow deterioration and markedly improve symptoms without reliably halting structural progression.

Injection-based options such as PRP, hyaluronic acid, or adipose-derived preparations can support the joint environment during the conservative phase — reducing inflammation and potentially improving lubrication — but structural arrest is not guaranteed, and the evidence base varies across preparations.

Waiting until pain becomes unbearable is not a neutral choice. Each period of ongoing impingement or cartilage stress adds incremental structural change — progressively narrowing the range of options that will remain available when treatment eventually becomes necessary. Some patients do remain stable for years without early intervention, and no evidence establishes a precise threshold — a particular age, BMI, or symptom duration — beyond which conservative care definitively fails. But stability and safety are not the same thing. One requires active verification; the other is simply the absence of an alarm.

The muscle and mobility toll of untreated hip OA

Cartilage loss gets most of the attention in conversations about hip OA, but the surrounding muscle toll is equally important — and far less often discussed.

Chronic hip pain tends to reduce the amount a person moves, and that reduction has a direct consequence: the hip abductor and gluteal muscles that stabilise the joint begin to weaken from disuse. Weaker muscles destabilise the hip, which worsens pain, which reduces activity further. The cycle reinforces itself. What begins as a joint problem progressively becomes a whole-limb problem.

The depth of this atrophy is striking. Research tracking patients two years after hip replacement — by which point most would expect a full recovery — found a remaining 6% hip muscle weakness compared to the other leg (Rasch, 2010). That figure comes from the post-surgical recovery period rather than from untreated patients directly, but it speaks to how profound the deficit can become during prolonged hip OA, and how long it takes to reverse.

Gait changes compound the picture. Pain shortens the time the foot spends on the affected side (antalgic gait), while abductor failure causes the pelvis to drop away from the affected hip during walking — the Trendelenburg sign. Both patterns throw extra load onto the contralateral hip and the joints below it, accelerating wear beyond the index joint. Fall risk also rises as abductor weakness and altered proprioception reduce the ability to correct sudden balance shifts.

The rehabilitation implication is direct: the sooner the disuse spiral is interrupted, the less muscle there is to rebuild afterwards, and the faster and more complete recovery tends to be.

When to seek a specialist assessment and what it involves

A GP review is a reasonable first step when hip pain appears, but certain signals suggest a hip specialist is the more appropriate next contact. Pain that has persisted beyond six to eight weeks, that limits walking to under 20–30 minutes, that routinely disturbs sleep, or that has not improved after a structured course of physiotherapy and analgesia — any of these warrants specialist-level assessment rather than continued watchful waiting. Patients with known FAI morphology, borderline dysplasia, or a family history of hip OA have additional grounds to seek assessment earlier, given the heightened structural risk discussed in the previous sections.

A specialist hip assessment typically covers four elements: a detailed history of symptom onset, pattern, and functional impact; physical examination of hip range of motion and abductor strength; weight-bearing X-ray to assess joint space and alignment; and, where soft-tissue detail is needed, MRI — including Open MRI for patients who cannot tolerate a standard scanner. The purpose is not simply to confirm OA is present. It is to place the hip accurately on the progression spectrum and establish whether cartilage-preserving options remain viable, or whether the joint has moved beyond that window.

Lincolnshire Hip, part of the MSK Doctors group, accepts patients without a GP referral. The service — led by Professor Paul Y. F. Lee — offers hip specialist consultations at clinics in Grantham and Sleaford, with the full assessment pathway available locally.

1. [1] Modern Hip Arthroscopy for FAIS May Delay the Natural History of Osteoarthritis in 25% of Patients: A 12-Year Follow-up Analysis. (2024). https://doi.org/10.1177/03635465241232154 https://doi.org/10.1177/03635465241232154
2. [2] Poster 197: Understanding the Biological Pathway of Progression of Hip OA Disease through Transcriptome Analysis. (2022). https://doi.org/10.1177/2325967121s00758 https://doi.org/10.1177/2325967121s00758
3. [3] The Pathophysiology and Progression of Hip OA Accompanied with Joint Pain — Follow-up Study of Hip OA Patients. (2014). https://doi.org/10.2174/1874312901408010046 https://doi.org/10.2174/1874312901408010046